NETRF reports progress in the development of neuroendocrine tumor cell lines to help eliminate a decades-old obstacle in laboratory research. To stimulate progress in NET cell lines, NETRF established a Cell Line Prize, funded cell line research, and launched a collaboration with a nationally known research institute. Each of these initiatives has succeeded in establishing NET cell lines.

NETRF welcomes five new members to its Board of Scientific Advisors, a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the diagnosis and treatment of neuroendocrine cancer.

Highlights from NANETS 2019 symposium where leading NET experts presented progress and identified priorities for moving NET knowledge and care forward.